Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
個股明細
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
SER
Serina Therapeutics, Inc.
NYSE AMERICAN
Biotechnology
United States
$2.73
▲
+0.04 (+1.49%)
CLOSED
—
OPEN
$2.70
HIGH
$2.74
LOW
$2.51
PREV CLOSE
$2.69
VOLUME
14.8K
0.20x avg
BID / ASK
2.59 / 2.74
spr 0.150
MARKET CAP
$69.3M
DAY RANGE
$2.51
$2.74
P/E (TTM)
—
Fwd -2.6
EPS (TTM)
-1.87
DIV YIELD
—
52W HIGH
$5.83
-53.2%
52W LOW
$1.22
+123.8%
BETA
0.09
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$2.72
-0.01
(-0.37%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
SER
$2.73
▲
+1.49%
Chart
Valuation
Financials
Peers
News
SER · K 線技術分析（即時、可互動）
basic
pro
快速分析（約半分鐘，最長 5 分鐘）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，通常約半分鐘，上游壅塞時最長 5 分鐘。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
一年走勢
RISK-OFF
252 BARS · -46.4% YOY
1-year price chart. Started at 5.09, currently 2.73, down 46.4 percent. Range 1.28 to 5.63 over 252 data points.
2025-09-05
$5.09 → $2.73 (-46.4%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
編輯內容 · 非投資建議。
資料來源：Finnhub（報價 / 公司資料 / 新聞 / 同業）＋ Yahoo（統計）＋ SEC EDGAR XBRL（財務 + DCF）。伺服器端數值經 ISR 快取，最長 60 分鐘；報價則在你的瀏覽器裡即時更新。
VALUATION
確定性估值（SEC EDGAR + Finnhub）
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
$0.94
WACC Used
+7.0%
Terminal g
+3.5%
判定: strong-sell
· peers $0.94 (-65.5%)
同業:
RNTX
TENX
SPRO PE9
FRMM
PMVP
XBIT
INMB
HRTX
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers.
FINANCIALS
多年財務（SEC XBRL）
RISK-ON
YOY REV +132.1% · 3 FY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
$130.0K
-$19.2M
-$18.0M
-$18.0M
$7.0M
2024-12
$56.0K
-$11.1M
-$17.1M
-$17.2M
$6.7M
2023-12
$3.2M
$5.3M
-$2.5M
—
$9.0M
PEERS
同業與產業對照
CALM
10 PEERS · FINNHUB
RNTX
TENX
SPRO
FRMM
PMVP
XBIT
INMB
HRTX
BOLD
NMAD
NEWS
近期新聞（過去 14 天）
CALM
8 HEADLINES · LAST 14 DAYS
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · 2026-08-13
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
GlobeNewswire · 2026-07-24
Serina Completes Enrollment, Dosing in First Cohort of Phase 1b Trial in Parkinson's Disease
MT Newswires · 2026-07-23
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
GlobeNewswire · 2026-07-23
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
GlobeNewswire · 2026-07-22
Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease
MT Newswires · 2026-07-09
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
GlobeNewswire · 2026-07-09
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
GlobeNewswire · 2026-06-30